Edition:
India

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

54.14USD
12:00am IST
Change (% chg)

$-0.18 (-0.33%)
Prev Close
$54.32
Open
$54.35
Day's High
$54.46
Day's Low
$53.81
Volume
42,886
Avg. Vol
63,942
52-wk High
$58.90
52-wk Low
$29.08

Latest Key Developments (Source: Significant Developments)

Anika Therapeutic Reports Q2 EPS Of $0.67
Thursday, 25 Jul 2019 

July 25 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.67.Q2 REVENUE $30.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $27.5 MILLION.SEES FY 2019 REVENUE UP 1 TO 4 PERCENT.Q2 EARNINGS PER SHARE ESTIMATE $0.39 -- REFINITIV IBES DATA.SAYS RAISES FULL YEAR 2019 REVENUE AND ADJUSTED EBITDA GUIDANCE.  Full Article

Anika Q1 Earnings Per Share $0.31
Friday, 3 May 2019 

May 2 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 EARNINGS PER SHARE $0.31.Q1 REVENUE $24.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $21.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.19 -- REFINITIV IBES DATA.ANNOUNCES $50 MILLION SHARE REPURCHASE PROGRAM.  Full Article

Anika Announces $50 Million Share Repurchase Program
Friday, 3 May 2019 

May 2 (Reuters) - Anika Therapeutics Inc ::ANIKA ANNOUNCES $50 MILLION SHARE REPURCHASE PROGRAM.ANIKA ANNOUNCES $50 MILLION SHARE REPURCHASE PROGRAM.ANIKA THERAPEUTICS INC - PLANS TO PURCHASE $30 MILLION OF SHARES UNDER AN ACCELERATED SHARE REPURCHASE (ASR) PROGRAM.ANIKA THERAPEUTICS INC - PLANS TO PURCHASE 20 MILLION OF SHARES FROM TIME TO TIME ON OPEN MARKET.ANIKA THERAPEUTICS INC - PLANS TO UTILIZE EXISTING CASH ON HAND TO FUND SHARE REPURCHASE PROGRAM..  Full Article

Anika Therapeutics Q2 Earnings Per Share $0.68
Thursday, 26 Jul 2018 

Anika Therapeutics Inc ::ANIKA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.68.Q2 REVENUE $30.5 MILLION VERSUS I/B/E/S VIEW $27.9 MILLION.Q2 EARNINGS PER SHARE VIEW $0.33 -- THOMSON REUTERS I/B/E/S.ANIKA THERAPEUTICS - CURRENTLY DOES NOT EXPECT LICENSING, MILESTONE AND CONTRACT REVENUE OF $5.0 MILLION IN 2018.CONTINUES TO ANTICIPATE PRODUCT REVENUE TO BE FLAT FOR FULL YEAR OF 2018.TOTAL OPERATING EXPENSES ARE NOW EXPECTED TO BE IN LOW $90 MILLION RANGE FOR FULL YEAR OF 2018.  Full Article

Anika Therapeutics Says Trial Of Knee Osteoarthritis Drug Misses Main Goal
Wednesday, 20 Jun 2018 

June 19 (Reuters) - Anika Therapeutics Inc ::ANIKA THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM CINGAL 16-02 CLINICAL TRIAL IN KNEE OSTEOARTHRITIS.ANIKA THERAPEUTICS INC - CINGAL 16-02 STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE AT PRIMARY ENDPOINT OF 26 WEEKS.ANIKA-CINGAL ACHIEVED GREATER PAIN REDUCTION NUMERICALLY AT EVERY TIME POINT IN STUDY, DIFFERENCE AT 26-WEEKS DID NOT REACH STATISTICAL SIGNIFICANCE.ANIKA-STRONG PAIN REDUCTION,OVERALL SYMPTOM RELIEF CONSISTENT WITH STATISTICALLY SIGNIFICANT RESULTS OF CINGAL 13-01 PHASE III PLACEBO-CONTROLLED STUDY.  Full Article

Anika Therapeutics Announces $30 Mln Accelerated Share Repurchase
Thursday, 24 May 2018 

May 23 (Reuters) - Anika Therapeutics Inc ::ANIKA THERAPEUTICS ANNOUNCES $30 MILLION ACCELERATED SHARE REPURCHASE.ANIKA THERAPEUTICS INC - PLANS TO UTILIZE EXISTING CASH ON HAND TO FUND ASR PROGRAM.ANIKA THERAPEUTICS INC - EXPECTS THAT ASR PROGRAM WILL COMMENCE IN LATE MAY AND THAT IT WILL BE COMPLETED IN Q4 OF 2018.  Full Article

Joseph Darling Named CEO And Director Of Anika Therapeutics
Tuesday, 6 Mar 2018 

March 5 (Reuters) - Anika Therapeutics Inc ::JOSEPH DARLING NAMED CEO AND DIRECTOR OF ANIKA THERAPEUTICS.ANIKA THERAPEUTICS - DARLING TO SUCCEED CHARLES SHERWOOD, WHO WILL RETIRE AS CEO AND A DIRECTOR OF ANIKA ON MARCH 9, 2018.  Full Article

Anika Q4 Earnings Per Share $0.53
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.53.Q4 REVENUE $29.4 MILLION VERSUS $28.7 MILLION.COMPANY EXPECTS TOTAL REVENUE GROWTH TO BE AROUND MID-SINGLE DIGIT PERCENTAGE RANGE FOR FULL YEAR OF 2018.  Full Article

Anika reports Q3 earnings per share $0.46
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika reports third quarter 2017 financial results.Q3 earnings per share $0.46.Q3 revenue rose 5 percent to $27.2 million.  Full Article

Anika completes enrollment in second pivotal phase III trial of cingal
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika Therapeutics - ‍Anika expects to complete cingal second pivotal phase III trial in first half of 2018 and anticipates FDA approval following year​.  Full Article